Why do you prescribe methylprednisolone for acute spinal cord injury? A Canadian perspective and a position statement

Canadian Journal of Neurological Sciences

Volumn 29, Issue 3, 2002, Pages 236-239

  Hurlbert, R J ^a   Moulton, R ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPREDNISOLONE;

ARTICLE; CANADA; CLINICAL TRIAL; EVIDENCE BASED MEDICINE; HUMAN; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; QUESTIONNAIRE; SPINAL CORD INJURY;

ACUTE DISEASE; ANTI-INFLAMMATORY AGENTS; CANADA; HUMANS; METHYLPREDNISOLONE; PRACTICE GUIDELINES; PRESCRIPTIONS, DRUG; QUESTIONNAIRES; SPINAL CORD INJURIES;

EID: 0036687790     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0317167100002006     Document Type: Article

References (8)

1. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury: Results of the second national acute spinal cord injury study
2. Methylprednisolone or naloxone treatment after acute spinal cord injury: 1-Year follow-up data
3. Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury
4. Methylprednisolone or tirilazad mesylate administration after acute spinal cord injury: 1-Year follow-up
5. Methylprednisolone for acute spinal cord injury: An inappropriate standard of care
6. Steroids and spinal cord injury: Revisiting the NASCIS 2 and NASCIS 3 trials
7. A critical appraisal of the reporting of the National Acute Spinal Cord Injury Studies (II and III) of methylprednisolone in acute spinal cord injury
8. High dose methylprednisolone in the management of acute spinal cord injury - A systematic review from a clinical perspective